MedTrace Logo

A Study of BGM0504 in Chinese Patients With Type 2 Diabetes

NCT06974825 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2025-05-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of BGM0504 in Chinese patients with Type 2 Diabetes.

Conditions

Interventions

DRUG

BGM0504 Administered SC

5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

DRUG

BGM0504 Administered SC

Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.

DRUG

BGM0504 Administered SC

Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.

DRUG

Semaglutide Administered SC

Active Comparator: 1 mg Semaglutide 1 mg semaglutide administered SC once a week

DRUG

Placebo Administered SC

Placebo Comparator: Placebo Placebo administered SC once a week.

Sponsors & Collaborators

  • BrightGene Bio-Medical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-30
Primary Completion
2024-08-13
Completion
2024-08-13
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06974825 on ClinicalTrials.gov